When it comes to lung cancer risk, we usually think first of smoking—and with good reason. But a new study suggests that what’s on your plate might also play a surprising role. Researchers from the ...

Cindy was a healthy, 35-year-old woman with no symptoms of cancer when she joined the American Lung Association’s Lung Health ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

Ian Smith, known as Harold Bishop in 'Neighbours', diagnosed with rare lung cancer: pulmonary pleomorphic carcinoma. Describes his diagnosis as a 'cruel, ugly, brutal place' with a feeling of ...

CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in ...

"Polydipsia" means "excessive thirst." It can be a symptom of medical conditions such as diabetes, a psychological symptom, ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

The intriguing VEGFxPD-1 bispecific antibody space gained oomph with phase III results disclosed April 23 by Akeso Pharmaceuticals Inc. related to Harmoni-6, testing ivonescimab in combination with ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...